Dr. Jérôme Galon is the Director of Research at INSERM (French NIH) and Head of the Laboratory of Integrative Cancer Immunology, in Paris, France. He was trained as an immunologist at the Pasteur Institute and the Curie Institute (Paris, France). He holds a Ph.D. degree in Immunology at the Jussieu University in 1996. Between 1997 and 2001, he worked at the NIH (National Institute of Health, Bethesda, USA). Since his full-tenured position at INSERM in 2001, he has directed interdisciplinary research programs on tumor Immunology. He is an associate Director and co-founder of the European Academy of Tumor Immunology (EATI), was in the board Director of the Society for Immunotherapy of Cancer (SITC). His work on the comprehensive analysis of the tumor microenvironment and the role of T-cells in human cancer led to the demonstration of the importance of adaptive pre-existing immunity in human cancer, and the concept of cancer immune-contexture. He pioneered the Immunoscore. He is the co-founder and CSO of HalioDx, now a Veracyte company. His contributions have been recognized with numerous awards, including the William B. Coley Award. In 2019, he was the winner of the prestigious European Inventor Award from the European Patent Office, and in 2021 awarded the Jeantet-Collen Prize (Switzerland) and the Galien Prize.